Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

The plan is to booster immunize the participants previously in 10μg test group in V-01 clinical trial phase I, 48 participants are planned to be enrolled. The actual case number will be calculated by the participants who signed the ICF and got actual inoculation with the third dose. Vaccination and follow-up: Three to six months after the two doses of V-01 (10 μg) were vaccinated, the participants received a booster dose of investigational vaccine (V-01, 10 μg) at the deltoid muscle of the upper arm. Perform safety and immunogenicity related inspections in accordance with the schedule in the plan.